Photoswitchable nanoparticles for in vivo cancer chemotherapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 47, 2013, Pages 19048-19053

  Tong, Rong ^a,b   Chiang, Homer H ^a   Kohane, Daniel S ^a  

^a Laboratory for Biomaterials and Drug Delivery   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; NANOCARRIER; PHOTOSWITCHABLE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; EX VIVO STUDY; FIBROSARCOMA; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ULTRAVIOLET IRRADIATION;

NANOMEDICINE; PHOTOSWITCHING; TRIGGERED DRUG DELIVERY;

ANTINEOPLASTIC AGENTS; BENZOPYRANS; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; INDOLES; NANOPARTICLES; NEOPLASMS; NITRO COMPOUNDS; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 84888091303     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1315336110     Document Type: Article

References (88)

1. Langer R (1993) Polymer-controlled drug-delivery systems. Acc Chem Res 26(10-537-542.
2. Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. Nature 263(5580-797-800.
3. Gref R, et al. (1994) Biodegradable long-circulating polymeric nanospheres. Science 263(5153-1600-1603.
4. Langer R (1998) Drug delivery and targeting. Nature 392(6679, Suppl-5-10.
5. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1-6387-6392.
6. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6-417-427.
7. Yuan F, et al. (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55(17-3752-3756.
8. Yuan F, et al. (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93(25-14765-14770.
9. Prabhakar U, et al. (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73(8-2412-2417.
10. Jain RK (1998) Delivery of molecular and cellular medicine to solid tumors. J Control Release 53(1-3-49-67.
11. Jain RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46(1-3-149-168.
12. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK (2000) Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res 60(16-4324-4327.
13. Padera TP, et al. (2004) Pathology: Cancer cells compress intratumour vessels. Nature 427(6976-695.
14. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60(9-2497-2503.
15. Stylianopoulos T, et al. (2012) Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA 109(38-15101-15108.
16. Tannock IF (1968) The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 22(2-258-273.
17. Denekamp J, Hobson B (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46(5-711-720.
18. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9(4-539-549.
19. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8-583-592.
20. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7(11-653-664.
21. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK (2011) Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Annu Rev Chem Biomol Eng 2(1-281-298.
22. Tong R, Hemmati HD, Langer R, Kohane DS (2012) Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J Am Chem Soc 134(21-8848-8855.
23. Minkin VI (2004) Photo-, thermo-, solvato-, and electrochromic spiroheterocyclic compounds. Chem Rev 104(5-2751-2776.
24. Corvera E, Mouritsen OG, Singer MA, Zuckermann MJ (1992) The permeability and the effect of acyl-chain length for phospholipid bilayers containing cholesterol: Theory and experiment. Biochim Biophys Acta 1107(2-261-270.
25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2-55-63.
26. Ramanujan S, et al. (2002) Diffusion and convection in collagen gels: Implications for transport in the tumor interstitium. Biophys J 83(3-1650-1660.
27. Sionkowska A, Wess T (2004) Mechanical properties of UV irradiated rat tail tendon (RTT) collagen. Int J Biol Macromol 34(1-2-9-12.
28. Ohlfest JR, Ivics Z, Izsvák Z (2009) Transposable Elements as Plasmid-Based Vectors for Long-Term Gene Transfer into Tumors. Gene Therapy of Cancer, Methods in Molecular Biology, eds Walther W, Stein US (Humana Press, New York), Vol 542, pp 105-116.
29. Kligman LH (1989) The ultraviolet-irradiated hairless mouse: A model for photoaging. J Am Acad Dermatol 21(3 Pt 2-623-631.
30. Yano K, Oura H, Detmar M (2002) Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-Binduced angiogenesis and cutaneous photo-damage. J Invest Dermatol 118(5-800-805.
31. Sawane M, Kajiya K (2012) Ultraviolet light-induced changes of lymphatic and blood vasculature in skin and their molecular mechanisms. Exp Dermatol 21(Suppl 1-22-25.
32. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere- A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6(3-339-355.
33. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9(5-1909-1915.
34. Lee H, Fonge H, Hoang B, Reilly RM, Allen C (2010) The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 7(4-1195-1208.
35. Tang L, Fan TM, Borst LB, Cheng J (2012) Synthesis and biological response of sizespecific, monodisperse drug-silica nanoconjugates. ACS Nano 6(5-3954-3966.
36. Cabral H, et al. (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6(12-815-823.
37. Cheng J, et al. (2007) Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5-869-876.
38. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4-505-515.
39. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications. Cancer Res 59(15-3776-3782.
40. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3(12-2431-2438.
41. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13-2825-2831.
42. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD (2001) Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 7(9-2862-2869.
43. Lu D, Wientjes MG, Lu Z, Au JL-S (2007) Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 322(1-80-88.
44. Wong HL, Shen Z, Lu Z, Wientjes MG, Au JLS (2011) Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. Mol Pharm 8(3-833-840.
45. Thurston G, Baluk P, Hirata A, McDonald DM (1996) Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol 271(6-H2547-H2562.
46. Hashizume H, et al. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4-1363-1380.
47. Chang YS, et al. (2000) Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97(26-14608-14613.
48. Chauhan VP, et al. (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7(6-383-388.
49. Netti PA, et al. (1999) Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules. Proc Natl Acad Sci USA 96(6-3137-3142.
50. Yuan F, et al. (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54(17-4564-4568.
51. Pluen A, et al. (2001) Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 98(8-4628-4633.
52. Timko BP, Dvir T, Kohane DS (2010) Remotely triggerable drug delivery systems. Adv Mater 22(44-4925-4943.
53. Tong R, Kohane DS (2012) Shedding light on nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 4(6-638-662.
54. Berkovic G, Krongauz V, Weiss V (2000) Spiropyrans and spirooxazines for memories and switches. Chem Rev 100(5-1741-1754.
55. Srinivasan S, et al. (2003) Interpreting hemoglobin and water concentration, oxygen saturation, and scattering measured in vivo by near-infrared breast tomography. Proc Natl Acad Sci USA 100(21-12349-12354.
56. Perry SW, Burke RM, Brown EB (2012) Two-photon and second harmonic microscopy in clinical and translational cancer research. Ann Biomed Eng 40(2-277-291.
57. Marriott G, et al. (2008) Optical lock-in detection imaging microscopy for contrastenhanced imaging in living cells. Proc Natl Acad Sci USA 105(46-17789-17794.
58. Liu Q, Yang T, Feng W, Li F (2012) Blue-emissive upconversion nanoparticles for lowpower- excited bioimaging in vivo. J Am Chem Soc 134(11-5390-5397.
59. Jayakumar MKG, Idris NM, Zhang Y (2012) Remote activation of biomolecules in deep tissues using near-infrared-to-UV upconversion nanotransducers. Proc Natl Acad Sci USA 109(22-8483-8488.
60. Weissleder R (2001) A clearer vision for in vivo imaging. Nat Biotechnol 19(4-316-317.
61. Yelin D, et al. (2006) Three-dimensional miniature endoscopy. Nature 443(7113-765.
62. Flusberg BA, et al. (2005) Fiber-optic fluorescence imaging. Nat Methods 2(12- 941-950.
63. Pathak MA, Fitzpatrick TB (1992) The evolution of photochemotherapy with psoralens and UVA (PUVA- 2000 BC to 1992 AD. J Photochem Photobiol B 14(1-2-3-22.
64. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PMM (1998) Nonsurgical repigmentation therapies in vitiligo. Meta-Analysis of the literature. Arch Dermatol 134(12-1532-1540.
65. Bethea D, et al. (1999) Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J Dermatol Sci 19(2-78-88.
66. Hafezi F, Kanellopoulos J, Wiltfang R, Seiler T (2007) Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. J Cataract Refract Surg 33(12-2035-2040.
67. Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T (2007) Safety of UVA-riboflavin crosslinking of the cornea. Cornea 26(4-385-389.
68. de Gruijl FR, et al. (1993) Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. Cancer Res 53(1-53-60.
69. Bowden GT (2004) Prevention of non-melanoma skin cancer by targeting ultraviolet- B-light signalling. Nat Rev Cancer 4(1-23-35.
70. Jiang W, Kim BYS, Rutka JT, Chan WCW (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3-145-150.
71. Popovic Z, et al. (2010) A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl 49(46-8649-8652.
72. Perry JL, et al. (2012) PEGylated PRINT nanoparticles: The impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett 12(10-5304-5310.
73. Tang L, et al. (2012) Aptamer-functionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors. Angew Chem Int Ed Engl 51(51-12721-12726.
74. Choi CHJ, Alabi CA, Webster P, Davis ME (2010) Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 107(3- 1235-1240.
75. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumorspecific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104(39-15549-15554.
76. Kong G, Braun RD, Dewhirst MW (2000) Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res 60(16-4440-4445.
77. Ponce AM, et al. (2007) Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. J Natl Cancer Inst 99(1-53-63.
78. Alberici L, et al. (2013) De novo design of a tumor-penetrating peptide. Cancer Res 73(2-804-812.
79. Sugahara KN, et al. (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981-1031-1035.
80. Ren Y, et al. (2012) Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 4(147-ra112.
81. McKee TD, et al. (2006) Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 66(5-2509-2513.
82. Mok W, Boucher Y, Jain RK (2007) Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 67(22-10664-10668.
83. Brown E, et al. (2003) Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9(6-796-800.
84. Provenzano PP, et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3-418-429.
85. Liu J, et al. (2012) TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci USA 109(41-16618-16623.
86. Kano MR, et al. (2007) Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci USA 104(9-3460-3465.
87. Gillies RJ, Schornack PA, Secomb TW, Raghunand N (1999) Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1(3-197-207.
88. Hamberg LM, Kristjansen PEG, Hunter GJ, Wolf GL, Jain RK (1994) Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 microliter resolution. Cancer Res 54(23-6032-6036.